Literature DB >> 22102607

Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.

Christopher C Dvorak1, Brian T Fisher, Lillian Sung, William J Steinbach, Michael Nieder, Sarah Alexander, Theoklis E Zaoutis.   

Abstract

A severe complication of the treatment of pediatric cancers is the development of an invasive fungal infection (IFI). The data to support antifungal prophylaxis in pediatric oncology patients derive primarily from adult patients, and thus the optimal agent to utilize is not clear. Fluconazole has been a standard option, but agents with antimold activity are now available, each with limitations. Pediatric dosing for voriconazole and posaconazole is uncertain and multiple drug interactions exist. The echinocandins are well-tolerated, but only available in intravenous form. Ultimately, studies demonstrating biologic risk factors for the development of IFI may lead to personalized prophylactic strategies.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22102607      PMCID： PMC4008331          DOI： 10.1002/pbc.23415

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  58 in total

1.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

2.  Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival.

Authors:  A H Groll; M Kurz; W Schneider; V Witt; H Schmidt; M Schneider; D Schwabe
Journal:  Mycoses       Date:  1999       Impact factor: 4.377

3.  International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia.

Authors:  Thomas Lehrnbecher; Marie-Chantal Ethier; Theoklis Zaoutis; Ursula Creutzig; Alan Gamis; Dirk Reinhardt; Richard Aplenc; Lillian Sung
Journal:  Br J Haematol       Date:  2009-08-05       Impact factor: 6.998

4.  Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Authors:  Mats O Karlsson; Irja Lutsar; Peter A Milligan
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

5.  Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia.

Authors:  Samina Afzal; Marie-Chantal Ethier; L Lee Dupuis; Laureen Tang; Angela S Punnett; Susan E Richardson; Upton Allen; Oussama Abla; Lillian Sung
Journal:  Pediatr Infect Dis J       Date:  2009-12       Impact factor: 2.129

6.  Voriconazole pharmacokinetics and pharmacodynamics in children.

Authors:  Michael Neely; Teresa Rushing; Andrea Kovacs; Roger Jelliffe; Jill Hoffman
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

7.  Comparison of caspofungin and amphotericin B for invasive candidiasis.

Authors:  Jorge Mora-Duarte; Robert Betts; Coleman Rotstein; Arnaldo Lopes Colombo; Luis Thompson-Moya; Juanita Smietana; Robert Lupinacci; Carole Sable; Nicholas Kartsonis; John Perfect
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

8.  Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia.

Authors:  Lillian Sung; Alan Gamis; Todd A Alonzo; Allen Buxton; Kristen Britton; Joetta Deswarte-Wallace; William G Woods
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

9.  Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients.

Authors:  M Mikulska; A M Raiola; B Bruno; E Furfaro; M T Van Lint; S Bregante; A Ibatici; V Del Bono; A Bacigalupo; C Viscoli
Journal:  Bone Marrow Transplant       Date:  2009-03-23       Impact factor: 5.483

10.  Plasminogen alleles influence susceptibility to invasive aspergillosis.

Authors:  Aimee K Zaas; Guochun Liao; Jason W Chien; Clarice Weinberg; David Shore; Steven S Giles; Kieren A Marr; Jonathan Usuka; Lauranell H Burch; Lalith Perera; John R Perfect; Gary Peltz; David A Schwartz
Journal:  PLoS Genet       Date:  2008-06-20       Impact factor: 5.917
View more
  20 in total

1.  Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  K Yoshikawa; Y Nakazawa; Y Katsuyama; K Hirabayashi; S Saito; T Shigemura; M Tanaka; R Yanagisawa; K Sakashita; K Koike
Journal:  Infection       Date:  2014-02-25       Impact factor: 3.553

2.  Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology.

Authors:  Jessica E Morgan; Hadeel Hassan; Julia V Cockle; Christopher Lethaby; Beki James; Robert S Phillips
Journal:  Support Care Cancer       Date:  2016-09-11       Impact factor: 3.603

Review 3.  Current Management of Childhood Acute Myeloid Leukemia.

Authors:  Jeffrey E Rubnitz
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

Review 4.  Children's Oncology Group's 2013 blueprint for research: cancer control and supportive care.

Authors:  Lillian Sung; Theo Zaoutis; Nicole J Ullrich; Donna Johnston; Lee Dupuis; Elena Ladas
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

Review 5.  Childhood acute myeloid leukaemia.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba
Journal:  Br J Haematol       Date:  2012-09-12       Impact factor: 6.998

Review 6.  Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.

Authors:  C Michel Zwaan; Edward A Kolb; Dirk Reinhardt; Jonas Abrahamsson; Souichi Adachi; Richard Aplenc; Eveline S J M De Bont; Barbara De Moerloose; Michael Dworzak; Brenda E S Gibson; Henrik Hasle; Guy Leverger; Franco Locatelli; Christine Ragu; Raul C Ribeiro; Carmelo Rizzari; Jeffrey E Rubnitz; Owen P Smith; Lillian Sung; Daisuke Tomizawa; Marry M van den Heuvel-Eibrink; Ursula Creutzig; Gertjan J L Kaspers
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

7.  Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.

Authors:  E Brissot; F Rialland; X Cahu; M Strullu; N Corradini; C Thomas; N Blin; X Rialland; E Thebaud; P Chevallier; P Moreau; N Milpied; J L Harousseau; F Mechinaud; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

Review 8.  How I treat pediatric acute myeloid leukemia.

Authors:  Jeffrey E Rubnitz
Journal:  Blood       Date:  2012-05-07       Impact factor: 22.113

9.  Antifungal prophylaxis associated with decreased induction mortality rates and resources utilized in children with new-onset acute myeloid leukemia.

Authors:  Brian T Fisher; Marko Kavcic; Yimei Li; Alix E Seif; Rochelle Bagatell; Yuan-Shung Huang; Theoklis Zaoutis; Kari Torp; Kateri H Leckerman; Richard Aplenc
Journal:  Clin Infect Dis       Date:  2013-11-23       Impact factor: 9.079

10.  Attitudes toward infection prophylaxis in pediatric oncology: a qualitative approach.

Authors:  Caroline Diorio; Deborah Tomlinson; Katherine M Boydell; Dean A Regier; Marie-Chantal Ethier; Amanda Alli; Sarah Alexander; Adam Gassas; Jonathan Taylor; Charis Kellow; Denise Mills; Lillian Sung
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.